Skip to main content
SpringerLink
Log in
Book cover

Treatment of Psoriasis pp 121–139Cite as

Traditional systemic therapy II: retinoids and others (hydroxyurea, thiopurine antimetabolites, mycophenlic acid, sulfasalazine)

  • Chapter

  • 1181 Accesses

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

Many systemic agents are commonly used to treat generalized psoriasis. Although they are efficacious, their potential adverse effects require close monitoring. These agents can be used either alone or in combination therapy. In addition, they can be used as rotational or sequential therapies.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Napoli JL, Boerman MH, Chai X, Zhai Y, Fiorella PD (1995) Enzymes and binding proteins affecting retinoic acid concentrations. J Steroid Biochem Mol Biol 53: 497–502

    Article  PubMed  CAS  Google Scholar 

  2. Napoli JL (1996) Retinoic acid biosynthesis and metabolism. FASEB J 10: 993–1001

    PubMed  CAS  Google Scholar 

  3. Saurat JH (1999) Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol 41: S2–6

    Article  PubMed  CAS  Google Scholar 

  4. Torma H, Rollman O, Vahlquist A (1998) Interferon-g increases retinoic acid and 3,4-didehydroretinoic acid concentrations in cultured keratinocytes: a clue to the abnormal vitamin A metabolism in psoriatic skin. J Invest Dermatol 110: 551

    Google Scholar 

  5. Geiger JM, Saurat JH (1993) Acitretin and etretinate. How and when they should be used. Dermatol Clin 11: 117–129

    PubMed  CAS  Google Scholar 

  6. Ling MR (1999) Acitretin: optimal dosing strategies. J Am Acad Dermatol 41: S13–17

    Article  PubMed  CAS  Google Scholar 

  7. Soriatane package insert (2004) Palo Alto, CA: Connectics Corporation

    Google Scholar 

  8. Geiger JM, Czarnetzki BM (1988) Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies. Dermatologica 176: 182–190

    Article  PubMed  CAS  Google Scholar 

  9. Camisa C (2004) Handbook of psoriasis. Publishing Ltd, Malden, MA

    Google Scholar 

  10. Lebwohl M, Ali S (2001) Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 45: 649–661

    Article  PubMed  CAS  Google Scholar 

  11. Roenigk HH (1999) Acitretin combination therapy. J Am Acad Dermatol 41: S18–21

    Article  PubMed  Google Scholar 

  12. Katz HI, Waalen J, Leach EE (1999) Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 41: S7–S12

    Article  PubMed  CAS  Google Scholar 

  13. McNamara PJ, Jewell RC, Jensen BK, Brindley CJ (1988) Food increases the bioavailability of acitretin. J Clin Pharmacol 28: 1051–1055

    PubMed  CAS  Google Scholar 

  14. Nguyen EQH (2001) Systemic retinoids. In: CL Kulp-Shorten, SE Wolverton (eds): Comprehensive dermatologic drug therapy. WB Saunders Company, Philadelphia (PA), 269–310

    Google Scholar 

  15. McClure SL, Valentine J, Gordon KB (2002) Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf 25: 913–927

    Article  PubMed  CAS  Google Scholar 

  16. Roche Laboratories, data on file

    Google Scholar 

  17. Gollnick HP (1996) Oral retinoids: efficacy and toxicity in psoriasis. Br J Dermatol 135Suppl 49: 6–17

    Article  PubMed  CAS  Google Scholar 

  18. Wilson DJ, Kay V, Charig M, Hughes DG, Creasy TS (1988) Skeletal hyperostosis and extraosseous calcification in patients receiving long-term etretinate (Tigason). Br J Dermatol 119: 597–607

    Article  PubMed  CAS  Google Scholar 

  19. Yarbro JW (1969) Hydroxyurea in the treatment of refractory psoriasis. Lancet 2: 846–847

    Article  PubMed  CAS  Google Scholar 

  20. Leavell UW, Yarbro JW (1970) Hydroxyurea. A new treatment for psoriasis. Arch Dermatol 102: 144–150

    Article  PubMed  Google Scholar 

  21. Yamauchi PS, Rizk D, Kormeili T, Patnail R, Lowe NJ (2003) Current systemic therapies for psoriasis: where are we now? J Am Acad Dermatol 49: S66–77

    Article  PubMed  Google Scholar 

  22. Vogler WR, Bain JA, Huguley CM (1966) In vivo effect of hydroxyurea on orotic acid synthesis. Cancer Res 26: 1827–1831

    PubMed  CAS  Google Scholar 

  23. Klem EB (1978) Effects of antipsoriasis drugs and metabolic inhibitors on the growth of epidermal cells in culture. J Invest Dermatol 70: 27–32

    Article  PubMed  CAS  Google Scholar 

  24. Boyd AS, Neldner KH (1991) Hydroxyurea therapy. J Am Acad Dermatol 25: 518–524

    PubMed  CAS  Google Scholar 

  25. Burns DA, Sarkany I, Gaylarde P (1980) Effects of hydroxyurea therapy on normal skin: a case report. Clin Exp Dermatol 5: 447–449

    Article  PubMed  CAS  Google Scholar 

  26. Kennedy BJ, Smith LR, Goltx RW (1975) Skin changes secondary to hydroxyurea therapy. Arch Dermatol 111: 183–187

    Article  PubMed  CAS  Google Scholar 

  27. Stein KM, Shelley WB, Weinberg RA (1971) Hydroxyurea in the treatment of pustular psoriasis. Br J Dermatol 85: 81–85

    PubMed  CAS  Google Scholar 

  28. Wahba A, Cohen H, Bar-Eli M, Callily R (1979) Neutrophil chemotaxis in psoriasis. Acta Derm Venereol 59: 441–445

    PubMed  CAS  Google Scholar 

  29. Moschella SL, Greenwald MA (1973) Psoriasis with hydroxyurea. An 18-month study of 60 patients. Arch Dermatol 107: 363–368

    Article  PubMed  CAS  Google Scholar 

  30. Layton AM, Sheehan-Dare RA, Goodfield MJ, Cotterill JA (1989) Hydroxyurea in the management of therapy resistant psoriasis. Br J Dermatol 121: 647–653

    Article  PubMed  CAS  Google Scholar 

  31. Kumar B, Saraswat A, Kaur I (2001) Rediscovering hydroxyurea: its role in recalcitrant psoriasis. Int J Dermatol 40: 530–534

    Article  PubMed  CAS  Google Scholar 

  32. Hydrea package insert (2001) Princeton, NJ: Bristol-Myers Squibb Company

    Google Scholar 

  33. Kumar B, Saraswat A, Kaur I (2002) Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients. Clin Exp Dermatol 27: 8–13

    Article  PubMed  CAS  Google Scholar 

  34. Thurman WG, Bloedow C, Howe CD, Levin WC, Davis P, Lane M, Sullivan MP, Griffith KM (1963) A phase I study of hydroxyurea. Cancer Chemother Rep 29: 103–107

    PubMed  CAS  Google Scholar 

  35. Folan DW (1977) Severe reaction to hydroxyurea. Cutis 20: 95

    PubMed  Google Scholar 

  36. Heddle R, Calvert AF (1980) Hydroxyurea induced hepatitis. Med J Aust 1: 121

    PubMed  CAS  Google Scholar 

  37. Baker H (1982) Antimitotic drugs in psoriasis. In: EM Farber, AJ Cox (eds): Psoriasis: Proceedings of the Third International Symposium. Grune and Stratton, New York, 119–126

    Google Scholar 

  38. Samuels ML, Howe CD (1964) Renal abnormalities induced by hydroxyurea (NSC-32065) Cancer Chemother Rep 40: 9–13

    PubMed  CAS  Google Scholar 

  39. Snow JL, Gibson LE (1995) The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 131: 193–197

    Article  PubMed  CAS  Google Scholar 

  40. Kazlow Stern D, Tripp JM, Ho VC, Lebwohl M (2005) The use of systemic immune moderators in dermatology: an update. Dermatol Clin 23: 259–300

    Article  PubMed  CAS  Google Scholar 

  41. Sanderson J, Ansari A, Marinaki T, Duley J (2004) Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem 41: 294–302

    Article  PubMed  CAS  Google Scholar 

  42. Patel AA, Swerlick RA, McCall CO (2006) Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 55: 369–389

    Article  PubMed  Google Scholar 

  43. 35. Holme SA, Duley JA, Sanderson J, Routledge PA, Anstey AV (2002) Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. QJM 95: 439–444

    Article  PubMed  CAS  Google Scholar 

  44. Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32: 651–662

    PubMed  CAS  Google Scholar 

  45. du Vivier A, Munro DD, Verbov J (1974) Treatment of psoriasis with azathioprine. Br Med J 1: 49–51

    PubMed  Google Scholar 

  46. Zackheim HS, Glogau RG, Fisher DA, Maibach HI (1994) 6-Thioguanine treatment of psoriasis: experience in 81 patients. J Am Acad Dermatol 30: 452–458

    PubMed  CAS  Google Scholar 

  47. Mason C, Krueger GG (2001) Thioguanine for refractory psoriasis: a 4-year experience. J Am Acad Dermatol 44: 67–72

    Article  PubMed  CAS  Google Scholar 

  48. Anstey AV, Wakelin S, Reynolds NJ (2004) Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 151: 1123–1132

    Article  PubMed  CAS  Google Scholar 

  49. Tabloid package insert (2004) Research Triangle Park, NC: GlaxoSmithKline

    Google Scholar 

  50. Silvis NG, Levine N (1999) Pulse dosing of thioguanine in recalcitrant psoriasis. Arch Dermatol 135: 433–437

    Article  PubMed  CAS  Google Scholar 

  51. Imuran package insert (2001) San Diego, CA: Prometheus Laboratories, Inc.

    Google Scholar 

  52. Kao NL, Rosenblate HJ (1993) 6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease. J Am Acad Dermatol 28: 1017–1018

    Article  PubMed  CAS  Google Scholar 

  53. de Boer NK, Jarbandhan SV, de Graaf P, Mulder CJ, van Elburg RM, van Bodegraven AA (2006) Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 101: 1390–1392

    Article  PubMed  Google Scholar 

  54. de Boer NK, van Elburg RM, Wilhelm AJ, Remmink AJ, van Vugt JM, Mulder CJ, van Bodegraven AA (2005) 6-Thioguanine for Crohn’s disease during pregnancy: thiopurine metabolite measurements in both mother and child. Scand J Gastroenterol 40: 1374–1377

    Article  PubMed  CAS  Google Scholar 

  55. Norgard B, Pedersen L, Jacobsen J, Rasmussen SN, Sorensen HT (2004) The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther 19: 679–685

    Article  PubMed  CAS  Google Scholar 

  56. Rajapakse RO, Korelitz BI, Zlatanic J, Baiocco PJ, Gleim GW (2000) Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 95: 684–688

    Article  PubMed  CAS  Google Scholar 

  57. Allison AC, Eugui EM (1996) Purine metabolism and immunosuppressive effects if mycophenolate mofetil (MMF). Clin Transplant 10: 77–84

    PubMed  CAS  Google Scholar 

  58. Geilen CC, Arnold M, Orfanos CE (2001) Mycophenolic mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol 144: 583–586

    Article  PubMed  CAS  Google Scholar 

  59. Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL (1997) Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 37: 445–449

    Article  PubMed  CAS  Google Scholar 

  60. Jones EL, Epinette WW, Hackney VC, Menendez L, Frost P (1975) Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 65: 537–542

    Article  PubMed  CAS  Google Scholar 

  61. Lynch WS, Roenigk HH (1977) Mycophenolic acid for psoriasis. Arch Dermatol 113: 1203–1208

    Article  PubMed  CAS  Google Scholar 

  62. Marinari R, Fleischmajer R, Schragger AH, Rosenthal AL (1977) Mycophenolic acid in the treatment of psoriasis: long-term administration. Arch Dermatol 113: 930–932

    Article  PubMed  CAS  Google Scholar 

  63. Gomez EC, Menendez L, Frost P (1979) Efficacy of mycophenolic acid for the treatment of psoriasis. J Am Acad Dermatol 1: 531–537

    PubMed  CAS  Google Scholar 

  64. Epinette WW, Parker CM, Jones EL, Greist MC (1987) Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 17: 962–971

    Article  PubMed  CAS  Google Scholar 

  65. Haufs MG, Beissert S, Grabbe S, Schutte B, Luger TA (1998) Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol 138: 179–181

    Article  PubMed  CAS  Google Scholar 

  66. Zhou Y, Rosenthal D, Dutz J, Ho V (2003) Mycophenolate mofetil (CellCept) for psoriasis: a twocenter, prospective, open-label clinical trial. J Cutan Med Surg 7: 193–197

    Article  PubMed  Google Scholar 

  67. CellCept package insert (2005) Nutley, NJ: Roche Laboratories

    Google Scholar 

  68. Myfortic package insert (2004) East Hanover, NJ: Novartis Pharmaceuticals Corporation

    Google Scholar 

  69. Mathew TH (1998) A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 65: 1450–1454

    Article  PubMed  CAS  Google Scholar 

  70. Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC (1991) RS-61443 — a new, potent immunosuppressive agent. Transplantation 51: 27–31

    Article  PubMed  CAS  Google Scholar 

  71. Ensley RD, Bristow MR, Olsen SL, Taylor DO, Hammond DH, O’Connell JB, Dunn D, Osburn L, Jones KW, Kauffman RS et al. (1993) The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 56: 75–82

    Article  PubMed  CAS  Google Scholar 

  72. Goldblum R (1993) Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exper Rheum 11: S117–119

    Google Scholar 

  73. Cohen HD, Das KM (2006) The metabolism of mesalamine and its possible use in colonic diver ticulitis as an anti-inflammatory agent. J Clin Gastroenterol 40: S150–154

    Article  PubMed  CAS  Google Scholar 

  74. Gupta AK, Ellis CN, Siegel MT, Duell EA, Griffiths CE, Hamilton TA, Nickoloff BJ, Voorhees JJ (1990) Sulfasalazine improves psoriasis. A double-blind analysis. Arch Dermatol 126: 487–493

    Article  PubMed  CAS  Google Scholar 

  75. Gupta AK, Ellis CN, Siegel MT, Voorhees JJ (1989) Sulfasalazine: a potential psoriasis therapy? J Am Acad Dermatol 20: 797–800

    Article  PubMed  CAS  Google Scholar 

  76. Schoch EP, McCuistion CH (1955) The effect of salicylazosulfapyridine (azulfidine) on pustular acne vulgaris and certain other dermatoses. J Invest Dermatol 25: 123–126

    PubMed  Google Scholar 

  77. Lorincz AL, Pearson RW (1962) Sulfapyridine and sulfone type drugs in dermatology. Arch Dermatol 85: 2–16

    PubMed  CAS  Google Scholar 

  78. Azulfidine package insert (2002) Kalamazoo, MI: Pharmacia Corporation

    Google Scholar 

  79. Lebwohl M (1999) Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 41: S22–24

    Article  PubMed  CAS  Google Scholar 

  80. Weinstein GD, White GM (1993) An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 28: 454–459

    PubMed  CAS  Google Scholar 

  81. Koo J (1999) Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 41: S25–28

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, St. Luke’s-Roosevelt Hospital Center, 1090 Amsterdam Avenue, Suite 11D, New York, NY, 10025, USA

    Sejal K. Shah & Jeffrey M. Weinberg

Authors
  1. Sejal K. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey M. Weinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Dermatology, St. Luke’s-Roosevelt Hospital Center, 1090 Amsterdam Avenue, Suite 11 D, New York, NY, 10025, USA

    Jeffrey M. Weinberg

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Shah, S.K., Weinberg, J.M. (2008). Traditional systemic therapy II: retinoids and others (hydroxyurea, thiopurine antimetabolites, mycophenlic acid, sulfasalazine). In: Weinberg, J.M. (eds) Treatment of Psoriasis. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-7724-3_8

Download citation

Publish with us

Policies and ethics

Search

Navigation